Cite
311 Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma
MLA
Michael Davies, et al. “311 Phase II Trial of Lymphodepletion plus Adoptive Cell Transfer with or without Dendritic Cell Vaccination in Patients with Metastatic Melanoma.” Journal for ImmunoTherapy of Cancer, vol. 8, no. Suppl 3, Nov. 2020. EBSCOhost, https://doi.org/10.1136/jitc-2020-SITC2020.0311.
APA
Michael Davies, Michael Wong, Sapna Patel, Cassian Yee, Adi Diab, Patrick Hwu, Cara Haymaker, Chantale Bernatchez, Rodabe Amaria, Hussein Tawbi, Isabella Glitza, Roland Bassett, Chantal Saberian, Marie Andree Forget, Gregory Lizee, & Jeniffer McQuade. (2020). 311 Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma. Journal for ImmunoTherapy of Cancer, 8(Suppl 3). https://doi.org/10.1136/jitc-2020-SITC2020.0311
Chicago
Michael Davies, Michael Wong, Sapna Patel, Cassian Yee, Adi Diab, Patrick Hwu, Cara Haymaker, et al. 2020. “311 Phase II Trial of Lymphodepletion plus Adoptive Cell Transfer with or without Dendritic Cell Vaccination in Patients with Metastatic Melanoma.” Journal for ImmunoTherapy of Cancer 8 (Suppl 3). doi:10.1136/jitc-2020-SITC2020.0311.